166 related articles for article (PubMed ID: 38230850)
1. Phenotype analysis of families with TP53 germline variants at the Center for Familial Breast and Ovarian Cancer, Cologne.
Kast K; Rhiem K; Larsen M; Wappenschmidt B; Schmutzler R
Cancer Med; 2024 Feb; 13(3):e6920. PubMed ID: 38230850
[TBL] [Abstract][Full Text] [Related]
2. TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge.
Grill S; Ramser J; Hellebrand H; Pfarr N; Boxberg M; Brambs C; Ditsch N; Meindl A; Groß E; Meitinger T; Kiechle M; Quante AS
Arch Gynecol Obstet; 2021 Jun; 303(6):1557-1567. PubMed ID: 33245408
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
[TBL] [Abstract][Full Text] [Related]
4. Li-Fraumeni syndrome in Tunisian carriers with different and rare tumor phenotype: genotype-phenotype correlation.
Sassi H; Meddeb R; Cherif MA; Nasr C; Riahi A; Hannachi S; Belguith N; M'rad R
BMC Med Genomics; 2022 Mar; 15(1):44. PubMed ID: 35246108
[TBL] [Abstract][Full Text] [Related]
5. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.
Kumamoto T; Yamazaki F; Nakano Y; Tamura C; Tashiro S; Hattori H; Nakagawara A; Tsunematsu Y
Int J Clin Oncol; 2021 Dec; 26(12):2161-2178. PubMed ID: 34633580
[TBL] [Abstract][Full Text] [Related]
6. Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil.
Matzenbacher Bittar C; de Araújo Rocha YM; Vieira IA; Rosset C; Andreis TF; Sartor ITS; Artigalás O; Netto CBO; Alemar B; Macedo GS; Ashton-Prolla P
PLoS One; 2021; 16(9):e0251639. PubMed ID: 34529667
[TBL] [Abstract][Full Text] [Related]
7.
da Silva PFF; Goveia RM; Teixeira TB; Gamba BF; de Lima AP; Rogatto SR; Silveira-Lacerda EP
Biomolecules; 2022 Apr; 12(5):. PubMed ID: 35625568
[No Abstract] [Full Text] [Related]
8. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
9. Next generation sequencing is informing phenotype: a TP53 example.
O'Shea R; Clarke R; Berkley E; Giffney C; Farrell M; O'Donovan E; Gallagher DJ
Fam Cancer; 2018 Jan; 17(1):123-128. PubMed ID: 28509937
[TBL] [Abstract][Full Text] [Related]
10. Identification and Management of
Pal T; Brzosowicz J; Valladares A; Wiesner GL; Laronga C
South Med J; 2017 Oct; 110(10):643-648. PubMed ID: 28973705
[TBL] [Abstract][Full Text] [Related]
11. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM
Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767
[TBL] [Abstract][Full Text] [Related]
12. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
[TBL] [Abstract][Full Text] [Related]
13. The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.
Escudeiro C; Pinto C; Vieira J; Peixoto A; Pinto P; Pinheiro M; Santos C; Guerra J; Lisboa S; Santos R; Silva J; Leal C; Coimbra N; Lopes P; Ferreira M; Sousa AB; Teixeira MR
Fam Cancer; 2021 Jul; 20(3):173-180. PubMed ID: 33051812
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
[TBL] [Abstract][Full Text] [Related]
15. Challenging interpretation of germline TP53 variants based on the experience of a national comprehensive cancer centre.
Butz H; Bozsik A; Grolmusz V; Szőcs E; Papp J; Patócs A
Sci Rep; 2023 Aug; 13(1):14259. PubMed ID: 37653074
[TBL] [Abstract][Full Text] [Related]
16. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
[TBL] [Abstract][Full Text] [Related]
17. Apparently Heterozygous TP53 Pathogenic Variants May Be Blood Limited in Patients Undergoing Hereditary Cancer Panel Testing.
Mester JL; Jackson SA; Postula K; Stettner A; Solomon S; Bissonnette J; Murphy PD; Klein RT; Hruska KS
J Mol Diagn; 2020 Mar; 22(3):396-404. PubMed ID: 31881331
[TBL] [Abstract][Full Text] [Related]
18. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
Fortuno C; James PA; Spurdle AB
Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
[TBL] [Abstract][Full Text] [Related]
19. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
[TBL] [Abstract][Full Text] [Related]
20. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically.
Coffee B; Cox HC; Bernhisel R; Manley S; Bowles K; Roa BB; Mancini-DiNardo D
Hum Mutat; 2020 Jan; 41(1):203-211. PubMed ID: 31490007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
